Researchers identified predictors of flares during and after pregnancy in patients with inactive or stable disease activity and characterized and estimated the frequency of postpartum flares.
An update to rosacea treatment guidelines provides a comprehensive summary of management options, including expert evaluations–based on the phenotypes of each patient–to serve as a guide for tailoring treatment and care.
Researchers evaluated the chronic damage associated with pregnancies before and after the diagnosis of systemic lupus erythematosus.
Mortality decrease greater in systemic lupus erythematosus pregnancies than in non-SLE pregnancies.
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Most patients report not having participated in a lupus clinical trial, despite interest.
The Food and Drug Administration (FDA) has approved the intravenous (IV) formulation of Benlysta (belimumab; GlaxoSmithKline) for the treatment of pediatric patients ≥5 years old with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
EULAR has released updated 2019 recommendations for the management of systemic lupus erythematosus.
The microbiome of patients with systemic lupus erythematosus (SLE), particularly those with increased disease activity, has reduced taxonomic complexity,.
Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.
